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Abstract
Background: Norwalk virus causes outbreaks of acute non-bacterial gastroenteritis in humans. The virus capsid
is composed of a single 60 kDa protein. In a previous study, the capsid protein of recombinant Norwalk virus
genogroup II was expressed in an E. coli system and monoclonal antibodies were generated against it. The analysis
of the reactivity of those monoclonal antibodies suggested that the N-terminal domain might contain more
antigenic epitopes than the C-terminal domain. In the same study, two broadly reactive monoclonal antibodies
were observed to react with genogroup I recombinant protein.
Results: In the present study, we used the recombinant capsid protein of genogroup I and characterized the
obtained 17 monoclonal antibodies by using 19 overlapping fragments. Sixteen monoclonal antibodies recognized
sequential epitopes on three antigenic regions, and the only exceptional monoclonal antibody recognized a
conformational epitope. As for the two broadly reactive monoclonal antibodies generated against genogroup II,
we indicated that they recognized fragment 2 of genogroup I. Furthermore, genogroup I antigen from a patient's
stool was detected by sandwich enzyme-linked immunosorbent assay using genogroup I specific monoclonal
antibody and biotinated broadly reactive monoclonal antibody.
Conclusion: The reactivity analysis of above monoclonal antibodies suggests that the N-terminal domain may
contain more antigenic epitopes than the C-terminal domain as suggested in our previous study. The detection
of genogroup I antigen from a patient's stool by our system suggested that the monoclonal antibodies generated
against E. coli expressed capsid protein can be used to detect genogroup I antigens in clinical material.
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Background
Norwalk viruses (NVs) are a small positive-stranded
RNA virus within the family Caliciviridae and consist of
genogroups I and II (GI and GII). An enzyme-linked im-
munosorbent assay (ELISA) system to detect all types of
NVs has not yet been established due to various clusters
of NVs in two genogroups. The lack of an in vitro culture
system might have hindered establishing a good detec-
tion system.
The genome of NV is approximately 7.6 kb in size, and
consists of three open reading frames (ORFs). The first
ORF encodes non-structural proteins, a capsid protein is
encoded by ORF2 and a function of the protein encoded
by ORF3 has been unknown [1,2]. However, recently it
was suggested that the ORF3 protein is a minor structur-
al protein of the virion [3].
Among the expression of cDNAs that encode NV capsid
proteins, the baculovirus recombinant system is most
common. Since all expressed recombinant proteins
spontaneously assembled into empty virus-like particles
(VLPs) in this system [4–9], immunological reaction of
generating antibodies using these VLPs is considered to
be similar to that when using native NV particles. The
availability of large amounts of recombinant NV (rNV)
VLPs has facilitated the production of polyclonal anti-
bodies as well as monoclonal antibodies (MAbs) useful to
develop immunological detection systems and charac-
terize antigenic sites of the virus. However, the antisera
generated against VLPs showed the specific reactivity.
These sera only reacted towards the closely related
strains of the same clusters [10–12].
In contrast to the specific reactivity of antibodies gener-
ated against VLPs, we showed broad reactivity of rabbit
IgG as well as two MAbs (generated against the E. coli-
expressed rNV GII capsid protein resulting in soluble
proteins without assembly into VLPs) in a previous study
[13,14]. We indicated the primary antigenic map of the
rNV36 (GII) capsid protein using MAbs generated
against it [14]. In the present study, 17 MAbs were gener-
ated against rNV96-908 (GI) capsid protein and 19 trun-
cated rNV fragments in addition to the whole capsid
protein were expressed in E. coli as antigens. The GI an-
tigenic map of rNV capsid protein using these Mabs was
constructed and the results compared with the former
GII antigenic map. We also clearly showed that two
MAbs generated against GII rNV36 reacted with frag-
ment 2 of rNV96-908 (GI). We obtained good results of
detecting NV in clinical material by sandwich ELISA us-
ing anti-G I MAb as the captured antibody and biotinat-
ed-broadly reactive MAb generated against GII, 1F6 (B-
1F6), as the detecting antibody. These results encour-
aged us to establish a good immunological detection sys-
tem.
Materials and Methods
Viruses, plasmid and E. coli
NV strains 36, 21, 114, 96–908, expression vector pTrx-
Fus*, E. coli (GI 724) strain and anti-NV36 MAbs used in
this study were prepared as described previously [13,14].
Other NV strains 99–8, and 00–001 were detected from
patients in our institute and strain Gifu'96 was isolated
and submitted to the Gifu Prefectural Institute for Bio-
industrial Technology.
Immunization of mice
MAbs specific to rNV96-908 were prepared from female
BALB/c mice immunized with recombinant thioredoxin
(TRX)-fused NV96-908 capsid protein (rTRX-NV96-
908) that had been partially purified as described previ-
ously [13]. Female BALB/c mice were immunized as de-
scribed previously [14].
Preparation of hybridoma
Cell fusion between lymphocytes and mouse myeloma
cells was performed as described previously [14].
Cloning of the rNV96-908 fragment gene in pTrx-Fus* ex-
pression vectors
The expression vector, pTrxFus* was used to construct
fusion proteins between TRX (thioredoxin, approxi-
mately 12 kDa) and NV96-908 fragment proteins. A total
of 19 overlapping fragments of the protein as well as the
whole NV96-908 capsid protein were expressed in E. coli
(Fig. 1, though two large domains are not shown).
These 19 overlapping fragments consisted of two large
fragments corresponding to the N-terminal domain
composed of residues 1–226 and the C-terminal domain
composed of residues 208–531 and 17 small fragments of
about 40 a.a. residues. All of the NV96-908 fragments
were generated using PCR with LA Taq DNA polymerase
(Takara Biomedicals, Japan). Most of the PCR experi-
ments consisted of 35 cycles of denaturation (94°C for 30
sec), primer annealing (55°C for 30 sec) and extension
(72°C for 1 min). For the primers G-l, -2, -3, -4, -5, -11, -
14 and Q-2, -3, -4, -5, -6, -12 and -15, PCR conditions
were as given above, except for primer annealing at 50°C.
The primers used in this experiment are shown in Table
1. All PCR products were digested with SmaI and XbaI
followed by purification on agarose gel, and were ligated
with SmaI and XbaI-digested pTrxFus* vectors. The li-
gation mixtures were used to transform GI724 compe-
tent cells.BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
Induction and analysis of recombinants
The resulting colonies carrying the expression constructs
were incubated, induced and analyzed as described pre-
viously [13]. The expression products were analyzed on
SDS-PAGE (Fig. 2). Both strands of the insert and junc-
tion of recombinant plasmids were sequenced using the
PRISM™ Dye-Deoxy Terminator Cycle Sequencing Kit
(Perkin Elmer ABI, USA) with the Trx-up and Trx-dw
and analyzed using the 310 Genetic analyzer (Perkin
Elmer ABI) as described previously [15].
Production and partial purification of recombinant pro-
teins
Recombinant proteins were produced from a 100 ml
tryptophan-induced culture of transformed E. coli. Puri-
fication of TRX-fusion proteins was performed by soni-
cation and centrifugation once, as described previously
[13]. Partial purification of the recombinant proteins was
performed as described before [14].
SDS-PAGE and immunoblotting analysis
Epitope mapping analysis
Purity of the fusion protein and protein concentrations
was estimated using Coomasie brilliant blue-stained
SDS-PAGE gels. WB assays were carried out according to
the methods described previously [13]. Briefly, the pro-
teins were transferred onto a NitranR membrane (Sch-
leicher & Schuell, Germany) using a Western transfer
buffer with semi-dry equipment, BP-312 (Bio-Craft, Ja-
pan). After blocking with Block Ace (Snow Brand, Ja-
pan), the membranes were incubated for 1 hr at 37°C
with MAbs diluted at various ratios in working buffer.
The dilution ratios used were: 1:100,000 to 1:250,000
for cloned MAbs (3E7, 4E6, 4F7, 7D2 and 13F9), 1:100 to
1:1,000 for culture sup. (1G9, 3D10, 4B10, 5B6, 6C4, 8C7,
8D2, 10F8, 10G10, 12D4 and 15G5). The membranes
were washed and incubated with horseradish peroxidase
(HRP)-conjugated anti-mouse-IgG Fc specific (Sigma)
diluted at 1:1,000 for 1 hr at room temperature (RT).
Bound antibodies were detected using 3, 3', 5, 5'-tetram-
ethylbenzidine (TMB) and membrane peroxidase sub-
strate system (Kirkegaard Perry Laboratories, USA). The
MAb, 7E9 was not tested, since it did not react in immu-
noblotting.
ELISA
A direct ELISA was carried out to determine the reactiv-
ity of the mouse MAbs with TRX-NV96-908 and TRX-
NV96-908 fragments. All of the reactions in ELISA were
performed in triplicate according to a methodology sim-
ilar to that described previously, except for adsorption
with 10 µg/ml TRX [13]. Briefly, 96-well microplates
were coated with 1 µg of the different antigens, TRX-
NV96-908, TRX-NV96-908 fragments and TRX, over-
night at 4°C. After washing 3 times, microplates were in-
cubated with anti-rNV96-908 mouse MAbs at various
concentrations for 1 hr at 37°C (Fig. 3a and 3b). HRP-la-
beled mouse IgG diluted at 1:5,000 was used as the sec-
ond antibody. After incubation for 1 hr at 37°C, bound
antibodies were detected by adding TMB as a substrate
followed by incubation for 30 min at RT. The enzyme re-
action was then stopped with 1 M phosphoric acid and
the absorbance measured at 450 nm in an ELISA micro-
plate reader. Model 550 (Bio-Rad, USA). The dilution ra-
tios of the MAbs were adjusted so that the OD value
showed less than 5 at 450 nm as indicated in Fig. 3. A
double antibody sandwich-ELISA (DAS-ELISA) was
used to determine the existence inhibition between the
reaction of rGI specific MAbs and the reaction of the
MAb 1F6 using rNV96-908. The detection sensitivity to
different GI rNV strains was also examined in the same
DAS-ELISA. The MAb 1F6 was biotinated using EZ-Link
NHS-Biotin (PIERCE, USA) according to the manufac-
ture's protocol. Then, 96-well microplates were coated
with 1 µg of two MAbs (3E7 and 4E6). After washing, var-
ious concentrations (0, 3.125, 6.25, 12.5, 25, 50, 100 and
200 ng/ml) of rNVs (TRX-NV36, 96–908, and 00–002)
and TRX were added to each well and incubated for 1 hr
at 37°C. After washing, the microplates were incubated
for 1 hr at 37°C with the biotinated (B)-antibody, B-1F6.
The Vectastain ABC Kit PK-6100 (Vector Laboratories,
USA) was used as a conjugate. After incubation with
Figure 1
Schematic diagram of rNV96-908 capsid fragments expressed
in  E. coli. The solid bar represents the full length of the
rNV96-908 capsid protein. Numbers besides the bar show
nucleotide numbers of NV96-908 capsid. Numbers above the
bar indicate the planned position of the fragment edges not
the actual positions. Small open boxes with numbers indicate
each fragment. The N-terminal fragment consists of frag-
ments 1–7 and the C-terminal fragment consists of fragments
8–17. These fragments were constructed using restriction
enzyme sites in primers for ligation convenience (Table 2).BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
Vectastain ABC for 30 min at 37°C, bound antibodies
were detected by adding TMB, as in the direct ELISA.
Detection of Norwalk virus from a patient's stool sample 
by sandwich ELISA
A DAS-ELISA was performed to detect NVs in a patient's
stool sample. The entire procedure in DAS-ELISA was
similar to other DAS-ELISA except for using clinical ma-
terials as antigens (100 µl/well).
Pre-treatment of clinical material (patient's stool)
After making 10% homogenized solution using saline,
centrifuging at 15,000 rpm. for 20 min at 4°C, the super-
natant was put into new tubes containing Block Ace (fi-
nal concentration 20%), and 2-Mercaptoethanol (2ME,
Wako Pure Chemical Industries, LTD, Japan) to reach a
final concentration of 2.5%. Four types of treatments
were carried out. 1) Heat treatment: incubate sample for
5 min at 100°C. 2) SDS/heat treatment: Add SDS into
sample to reach a final concentration of 1%, incubate for
5 min at 100°C. 3) Alkaline treatment: add 1 M NaOH
into the sample to reach a final concentration of 0.18 M
(approximately pH 10), incubate for 10 min at RT. Then,
add 1.5 fold vol. of 1 M Tris-HCl (pH 6.8) into the sample
to make pH approximately 8.4. 4) Freeze and thaw treat-
ment: samples were frozen and thawed twice after alka-
line and neutralization treatment (freeze at -80°C until
the samples become frozen, then thaw at 37°C).
Results and Discussion
Recombinant Proteins
Nineteen trumcated pTrx-Fus recombinant plasmids de-
rived from pTrx-Fus-NV96-908 were constructed con-
taining overlapping fragments of NV96-908 at various
lengths, as shown in Fig. 1. Production of rNV96-908
fragments in E. coli were verified by Coomassie brilliant
blue staining of SDS-PAGE gels (Fig. 2). Expression lev-
els varied widely, with the amount of purified fragment
Figure 2
Expression of the rNV96-908 fragments in E. coli. Production of TRX-fused capsid protein fragments in E. coli was analyzed by
staining two SDS-PAGE gels. From the left, lane 1 and lane 21 : marker [kDa], lane 2 and lane 2: control recombinant E. coli
lysate (before induction). From lane 3 to 23 except 21 and 22 are TRX-NV96-908 N-terminal domain, C-terminal domain, frag-
ment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and 17, respectively. The positions of the recombinant NV capsid frag-
ments are indicated by arrows (the small fragments show similar molecular weights).BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
ranging from 0.1 to 8 mg/ml (yield 0.05 mg to 4 mg). The
concentration of purified fragments was estimated by
visual comparison with known quantities of bovine se-
rum albumin (BSA) in SDS-PAGE gels.
Production and preliminary characterization of rNV-spe-
cific MAbs
A total of 17 anti-rNV96-908 MAbs have been obtained.
Their specificity in preliminary immuno-reactions to
whole NV capsid protein, as well as to the N-terminal do-
main (NV96-908 residues 1–226) and C-terminal do-
Figure 3
Antigenic sites on rNV96-908 defined by MAbs using the N-terminal (a) and the C-terminal fragments (b) as antigens. Reactiv-
ity of MAbs with rNV96-908 derived fragments was measured by ELISA. Names of the individual MAbs and their dilutions used
are shown at the bottom of the figures.
Table 1: Primers used in this experiment
LI: TCC CCCGGG ATG ATG ATG GCG TCT AAG GAC L2: GC TCTAGA TTA TWW WCG GCG CAV WCC AAG CC
G1: TCC CCCGGG CTT GCA ATG GAT CCT GTG GC Ql: GC TCTAGA ACT GCT GTT GAA GAA CCC GC
G2: TCC CCCGGG CAA GGT GAA TTT ACT ATT TC Q2: GC TCTAGA AAT AGT AAA TTC ACC TTG GG
G3: TCC CCCGGG CTT AAT CCC TTC TTG TTA C Q3: GC TCTAGA TGC CAA CCC AGC CAT TAT AC
G4: TCC CCCGGG GGT AAA ATT ATA GTT TCT TGC Q4: GC TCTAGA AAT CAC ATG CGG GAA GAG AG
G5: TCC CCCGGG GAT GTA AGG AAT GTT CTC TTT C Q5: GC TCTAGA CTT ACA TCT ACT AAG GGT AC
G6: TCC CCCGGG CAA ACA ATG CGC CTT GTG TGC Q6: GC TCTAGA GGA GGG GGG TGT AAA GCA TG
G7: TCC CCCGGG ACT TGT CCT AGC CCC GAT TTC Q7: GC TCTAGA GTT CCA CTG TGG GAG GAA CC
G8: TCC CCCGGG TTG TCA AAT TCA CGT GCC CC Q8: GC TCTAGA AAT TGG AAG AGG GGC ACG TG
G9: TCC CCCGGG TGT ACC TTA GAT GGA CGA C Q9: GC TCTAGA GGT GGT ACC AAC AAG TCG TC
G10: TCC CCCGGG GGT ACT TCT AAT GGT ACT GTG Q10: GC TCTAGA GGG GCA GGG CCT TCA AAA GG
G11: TCC CCCGGG GAT TGG CAT ATT AAC ATG AC Q11: GC TCTAGA TGA GTC TGG CTA GAA TGT CC
G12: TCC CCCGGG GGT TCA ATC CAG GCG AAT GG Q12: GC TCTAGA TAA GAA CAC CAA TGT AGT TG
G13: TCC CCCGGG AAG ATC CCC AAC TAT GGG TC Q13: GC TCTAGA CTG TGA TGC TAG ACC CAT AG
G14: TCC CCCGGG TTC ATG TCA AAG ATA CCA GG Q14: GC TCTAGA AAG CAC CAG GGC CTG GTA TC
G15: TCC CCCGGG CCC ACT GTT GGT GAA GCC GC Q15: GC TCTAGA TAG TGG AGT AGG GCG GCT TC
G16: TCC CCCGGG GAT GGT TTC CTA ACC TGT GTC Q16: GC TCTAGA GCT GGC CCC GTT AGG GAC AC
Trx-up: TTC CTC GAC GCT AAC CTG GC Trx-DW: GTA AA CGA CGG CCA GTG CC
G, L and Q primers were used for amplifying NV96-908 fragments, and Trx-up and Trx-dw primers for generating the insert and junction sequence 
of recombinant plasmids. These Trx primers have also been used for sequencing. Underlined sequences of G primers and LI primer shows the SmaI 
site, and that of bo th L2 primer and Q primers the XbaI site.BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
main (NV96-908 residues 208–531), using ELISA and
immunoblot analysis is shown in Table 2. In ELISA, 14
MAbs reacted with the N-terminal domain and 3 MAbs
reacted with the C-terminal domain. The findings of the
immunoblotting corresponded well with those of ELISA
except one MAb, 7E9. The MAb, 7E9 might recognize the
conformational epitope, since it did not react in immu-
noblotting.
Reactivity of rNV96-908-specific MAbs with the recom-
binant fragments determined with ELISA
To complete the epitope mapping, the reactivity of MAbs
to different areas of the N-terminal domain (fragments
1–7) and C-terminal domain (fragments 8–17) was de-
termined using ELISA (Fig. 3a and 3b). Thirteen of 14
MAbs (that reacted with the N-terminal domain) reacted
with fragment 1. One MAb (7E9) was suggested to recog-
nize the conformational epitope, since it reacted with the
N-terminal domain, but reacted with none of the frag-
ments (fragments 1–7) as shown in Fig. 3a. These results
explained why 7E9 did not react in the immunoblotting
test (Table 2).
Among the C-terminal domain recognition MAbs, two
MAbs, 10G10 and 5B6 showed a clear reactivity with
fragment 11, and one MAb, 8C7, reacted with fragment
16.
Characterization of rNV96-908 epitopes by immuoblotting
The findings of immunoblotting corresponded well to
those of ELISA with only one exception, MAb 7E9. Since
all MAbs except 7E9 recognized the sequential epitopes,
similar findings between imrnunoblotting and ELISA
should be as no surprise.
Antigenic domains of rNV96-908
The antigenic structure of the rNV96-908 capsid protein
appears to be characterized by the presence of three im-
munodominant regions based on the immuno-reactivity
of mouse MAbs towards the capsid protein (rNV96-908)
fragments (Fig. 4). Thirteen of 17 MAbs recognized frag-
ment 1, composed of 43 a.a. residues. Two of the 17 MAbs
recognized fragment 11, consisting of 51 a.a. residues,
and one MAb recognized fragment 16, with 39 a.a. resi-
dues. Comparisons of a.a. sequences of fragments 1,11
and 16 were carried out among various rNVs and refer-
ence NV strains (Fig. 5). Fragment 1 was suggested to
contain an antigenically dominant region that probably
includes several epitopes, since the MAbs reacted differ-
ently towards a different type of GI rNV002 (Chiba type).
Although data is not shown, three patterns of reaction
were observed; those that reacted with similar sensitivity
as rNV96-908, approximately 50% sensitivity, and those
that did not react. There might not be common epitopes
between GI and GII in fragment 1, since only one MAb,
Table 2: Characterization and reactivity of MAbs to whole rNV96-908, and its N-terminal and C-terminal fragments(rNV-N, rNV-C).
Hybridoma Isotype Reactivity in ELISA Reactivity in WB




rNV-N rNV-C whole rNV96-
908
rNV-N rNV-C
3E7 IgG1 (k) ++ ++ - ++ ++ -
4E6 lgG2b (k) ++ ++ - ++ ++ -
4F7 lgG2a (k) ++ ++ - ++ ++ -
7D2 lgG2b (k) ++ ++ - ++ + -
7E9 lgG2b (k) ++ ++ - - - -
13F9 lgG2b (k) ++ ++ - ++ ++ -
1G9 Not cloned ++ ++ - ++ ++ -
3D10 Not cloned ++ ++ - ++ ++ -
4B10 Not cloned ++ ++ - ++ ++ -
5B6 Not cloned ++ - ++ ++ - ++
6C4 Not cloned ++ ++ - ++ ++ -
8C7 Not cloned ++ - ++ ++ - ++
8D2 Not cloned ++ ++ - ++ ++ -
10F8 Not cloned ++ ++ - ++ ++ -
10G10 Not cloned ++ - ++ ++ - ++
12D4 Not cloned ++ ++ - ++ ++ -
15G5 Not cloned ++ ++ - ++ ++ -
- Negative reaction; + positive reaction; ++ strong positive reactionBMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
3E7 has weak cross-reactivity with one of the rNVs, GII
rNV36 (Mexico virus type). It is unclear whether those
MAbs that recognized fragment 1 on rNV96-908 had a
broad recognition range of GI rNV, since the cross-reac-
tivity with other GI rNV had not been examined except
for the Chiba type. Fine epitope mapping of cloned MAbs
that recognized fragment 1 of NV96-908 should be help-
ful to elucidate the possibility of MAbs application to de-
tect a broad range of GI NVs.
The MAbs, 10G10 and 5B6 recognized fragment 11 of
NV96-908, but did not react with GI rNV002 (Chiba
type). This finding suggested that fragment 11 of NV96-
908 probably did not contain common epitopes among
GI NVs. The MAb (8C7) that recognized fragment 16 re-
acted well with GI rNV002 (Chiba type). It might recog-
nize common epitopes among GI NVs.
Reactivity of broadly reactive MAbs generated against 
rNV36 (GII) with the recombinant fragments of NV96-908 
(GI) determined by ELISA
Since the cross-reactive MAbs generated against rNV36
(1B4 and 1F6) showed broad reactivity towards different
types of rNV capsid proteins by direct ELISA as indicated
in Fig. 6, ELISA was performed to determine epitopes of
these MAbs on rNV96-908 fragments. As expected, both
of the MAbs reacted with the N-terminal domain, but not
with the C-terminal domain, moreover, both reacted
with fragment 2 specifically among fragments 1 to 7 of
rNV96-908 as shown in Fig. 7. Comparison of amino
acid sequences of fragment 2 of rNV96-908 (GI) and that
of rNV36 (GII) with other rNVs, and their related refer-
ence strains are shown in Fig. 8. It might be difficult to
determine the fine epitopes of these two MAbs (1B4 and
1F6) with the present findings. However, it appears to be
important to elucidate fine epitopes of these MAbs for
further study.
Double antibody sandwich ELISA (DAS-ELISA)
Since one of the broadly reactive MAbs generated against
GII, 1F6, reacted with GI rNVs better than 1B4 as shown
in Fig. 6, 1F6 was used for a DAS-ELISA. MAbs, 3E7 and
4E6 were chosen from rNV96-908 specific MAbs since
these two MAbs reacted well with rNV002 (Chiba type).
Due to the close location between the epitopes 3E7 or
4E6 (fragment 1 of rNV96-908) and 1F6 (fragment 2 of
rNV96-908), a DAS-ELISA was carried out to examine
whether MAbs (3E7 and 4E6) inhibit the reaction of the
Biotinated-lF6 (B-1F6). Two rGI NV specific MAbs were
used as captured Abs, and B-1F6 was used as detecting
Ab. The results indicated that these two anti-GI NV
MAbs did not inhibit the reaction of B-lF6 as indicated in
Fig. 9a and 9b. Recombinant NV002 can be detected as
sensitive as NV96-908 in an appropriate detection area
in these systems. Since one of the anti-GI NV MAbs, 3E7
showed weak cross-reactivity towards GII rNV36, rNV
36 could be detected as shown in Fig. 9(b) but not in 9(a).
Detection of Norwalk virus from a patient's stool by sand-
wich ELISA
A sandwich ELISA was performed to detect NV from a
patient's stool using the rGI NV specific monoclonal an-
Figure 4
Diagram of rNV antigenic domains. The gray bar at the top
represents the full length of the rNV96-908 capsid protein.
The arrowhead shows the putative position of the trypsin
cleavage site. The N-terminal and C-terminal parts are
shown as open bars. The antigenic regions of fragments 1, 11
and 16 are indicated as dark gray color boxes. Reacting MAbs
are shown below the corresponding fragments. Numbers on
the top of the rNV capsid and the antigenic fragments indi-
cate the first and last residues.
Figure 5
Comparison of amino acid sequences of fragments 1 (a), 11
(b) and 16 (c) in two rNVs of GI strains and the related ref-
erence NV strains. The dotted lines show deletions and
under lined a.a. sequences are unique parts of the individual
fragments. Other parts are overlapping with proximal frag-
ments. Accession numbers for NV96-908, NV002, KY89 and
Chiba virus are AB028247, AB063325, L23828 and
AB022679, respectively.BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
tibody (3E7) as the captured antibody, biotinated 1F6
(generated against GII) as the detecting antibody. The
nucleotide sequence (nt) of equivalent parts in NV
strains from patients were obtained and a. a. residues
were compared with that of fragment 1 in rNV96-908
and that of fragment 2 in rNV36 prior to use. Amino acid
residues of the selected strain, 00–001 was similar to
fragments 1 and 2 of rNV96-908 (and suggested to be
recognized by both MAbs in this ELISA). As shown as
Fig. 10(a), the alkaline treatment appeared best for spe-
cific detection of the GI NV antigen among four pre-
treatments of the clinical material. On the other hand,
freezing and thawing after alkaline and neutralization
treatment appeared to change appropriate denaturation
of the NV antigen in the materials. Heat treatment with
or without SDS did not work at all. The existence of 2-
Mercaptoethanol (2ME) during these treatments was
significantly important, since none of the treatments
without 2ME could detect the GI NV antigen from clini-
cal material. Various concentrations of rNV protein were
used to obtain a calibration curve shown in Fig. 10(b).
Only some of the NV antigens in 00–001 sample were
considered to be detected by this system, because among
NV particles and capsid proteins in 00–001, some of the
Figure 6
Reactivity comparison of the broadly reactive MAbs gener-
ated against GII rNV36 towards various rNVs. Reactivity of
the MAbs (1B4 and 1F6) was measured by direct ELISA.
Among rNVs, strains 002 and 96–908 are GI and the others
are GII. Names of the individual MAbs and their dilutions (in
the parentheses) are indicated at the bottom of the figure.
Figure 7
Antigenic sites on rNV96-908 were defined by the broadly
reactive MAbs using the N- and C-terminal fragments as well
as fragments 1 to 7 as antigens. Reactivity of the MAbs
towards rNV96-908 derived fragments was measured by
ELISA. Names of the MAbs and their dilutions used are
shown at the bottom of the figure.
Figure 8
Comparison of amino acid fragment 2 of NV36 with other
rNVs and the reference NV strains. The underlined a.a.
sequences are unique parts of the individual fragments.
Other parts are overlapping with proximal fragments. Acces-
sion numbers for NV21, NV114, Gifu'96, Mexico virus and
Lordsdale virus are AB028245, AB028246, AB045603,
U22498 and X86557, respectively.BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
particles and capsid proteins were denatured in alkaline
buffer and partly maintained an adequate structure to be
detected by MAbs after neutralization. Although it is im-
possible to estimate the precise amount of NV capsid
protein in 00–001 from the calibration curve in (b), it
was estimated at approximately 22 ng/ml. Application of
this system should be examined using more clinical ma-
terials.
Conclusions
Fourteen of the 17 MAbs generated against the E. coli ex-
pressed GI NV96-908 capsid protein recognized the N-
terminal domain (equivalent residues 1–226). Thirteen
of 14 MAbs recognized fragment 1 (residues 1–43), and
only one exceptional MAb recognized the conformation-
al epitope. The remaining 3 MAbs recognized two differ-
ent fragments within the C-terminal domain (residues
208–531). These results suggest that the N-terminal do-
main may contain more antigenic epitopes than the C-
terminal domain. This suggestion appears different from
MAbs generated against rNV VLPs [16]. It might be bet-
ter using baculovirus expressed rNV VLPs for generating
Abs, since the immunological reaction appears similar to
that when using native NV particles. In contrast to the
highly specific reactivity of Abs generated against bacu-
lovirus expressed rNV VLPs [10–12], Abs generated
against E. coli expressed GII rNV showed broad reactiv-
ity. Broad and strong cross-reactivity of these MAbs gen-
erated against GII NV towards GI NV was clearly
elucidated by showing their specific reaction to fragment
2 on rNV96-908 in this study.
Instead of indicating NV Ag detection by WB analysis af-
ter purification [14], we indicated NV Ag detection by
ELISA using a simple pre-treated patient's stool sample
in this study. This is the first study that reported the ap-
plication of GI NV antigen detection from clinical mate-
rial using the MAbs generated against E. coli expressed
Figure 9
A double antibody sandwich ELISA for detecting various rNV antigens. The captured antibody in (a): 4E6 (GI specific MAb) and
(b): 3E7 (GI specific MAb), B-1F6 was used as the detecting antibody in both of the reaction.BMC Microbiology 2001, 1:24 http://www.biomedcentral.com/1471-2180/1/24
NV capsid protein. Furthermore complicated pre-treat-
ment of stool samples was not necessary and there ap-
pears to be the possibility to improve the NV Ag
detection system. Due to the lack of a good immunologi-
cal detection system, RT-PCR has been most common
NV Ag detection test. However, it is time consuming with
a complicated procedure. It appears to be significantly
important to indicate the application possibility of estab-
lishing a good immunological system using MAbs gener-
ated against E. coli expressed rNV.
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